Sunovion is presenting data from retrospective database analyses in two separate posters at the 2015 American College of Chest Physicians annual meeting that show similar rates of hospital readmission for COPD patients treated with Brovana arformoterol tartrate inhalation solution compared to fluticasone/salmeterol or tiotropium bromide.
Rates of 1-month all-cause readmissions were 20.8% for Brovana vs. 20.9% for fluticasone/salmeterol in the first study and 21.1% for Brovana vs. 22.1% for tiotropium in the second. There were also no significant differences in either study for 1-month COPD, 6-month all-cause, or 6-month COPD readmissions. Data for both studies came from patients hospitalized between January 1, 2011, and June 30, 2012.
Sunovion Head of Global Health Economics and Outcomes Research Krithika Rajagopalan commented, “Despite available treatments, at least 20 percent of all patients hospitalized with COPD will be readmitted within 30-days. These analyses assess the potential of long-acting bronchodilator nebulization, an often overlooked and underutilized modality, in comparison to other leading inhaled therapies to address hospital readmissions. Sunovion is committed to understanding and sharing critical health outcomes information that may improve current treatment paradigms for COPD patients.”
Read the Sunovion press release.
Read the poster abstract for Brovana vs. fluticasone/salmeterol
